Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q3 2022 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Rhythm Pharmaceuticals Third Quarter 2022 Earnings Conference Call.
Rhythm Pharmaceuticals Inc. (RYTM)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value (x$1000) | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Baker Bros. Advisors Julian Baker And Felix Baker | 6,062,702 | $148,536 | +47% | 0.97% |
| 2. | RA Capital Management Peter Kolchinsky | 5,471,067 | $134,041 | +13% | 2.85% |
| 3. | Rock Springs Capital Management Kris Jenner, Gordon Bussard, Graham Mcphail | 1,760,865 | $43,141 | +26% | 1.11% |
| 4. | Alkeon Capital Management Panayotis Takis Sparaggis | 1,705,000 | $41,773 | +14% | 0.13% |
| 5. | Opaleye Management James A. Silverman | 810,000 | $19,845 | +124% | 8.19% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $20.17 | 10,000 | Officer, Director | 111,335 | 2021-03-30 | Filing | |
| $26.42 | 378,501 | Director | 3,074,893 | 2018-06-25 | Filing | |
| $17.00 | 100,000 | Large Shareholder | 2,696,392 | 2017-10-10 | Filing | |
| $17.00 | 100,000 | Large Shareholder, Director | 2,696,392 | 2017-10-10 | Filing | |
| $17.00 | 550,000 | Large Shareholder | 4,909,956 | 2017-10-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $24.83 | 13,493 | Officer | 2,224 | 2022-08-19 | Filing | |
| $11.68 | 901 | Officer | 2,224 | 2022-07-27 | Filing | |
| $4.08 | 7,547 | Officer | 57,614 | 2022-07-01 | Filing | |
| $11.13 | 1,023 | Officer | 1,477 | 2022-03-29 | Filing | |
| $6.10 | 557 | Officer | 1,006 | 2022-02-15 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value (x$1000) | % Port |
|---|---|---|---|---|
| 1. | 153,202 | $4,461,242 | 0.25% | |
| 2. | 73,320 | $2,135,078 | 0.05% | |
| 3. | 6,879 | $200,316 | 0% | |
| 4. | 1,894,000 | $55,153 | 3.42% | |
| 5. | 463,516 | $13,498 | 0.04% |
News See All
12 Best Performing NASDAQ Stocks in 2022
The S&P 500 rose 0.6% to 3,844.82 on December 23, while the Nasdaq Composite gained 0.2% to close at 10,497.86. The Dow Jones Industrial Average also closed 176.44 points or 0.5% higher at 33,203.93.
12 Best Performing Biotech Stocks in 2022
Fitch Ratings has assigned a Neutral rating to the global pharmaceutical and biotech industry, which indicates the assumption of a collaborative operating backdrop in 2023, although inflationary pressures...
5 Best-Performing Small-Cap Stocks of 2022
NextDecade Corporation (NASDAQ:NEXT) is a Texas-based company engaged in the liquefaction and sale of liquefied natural gas, as well as capture and storage of carbon dioxide emissions.
Were Hedge Funds Right About Piling Into Rhythm Pharmaceuticals, Inc. (RYTM)?
While the market driven by short-term sentiment influenced by the accommodative interest rate environment in the US, virus news and stimulus spending, many smart money investors are starting to get cautious...
Is RYTM A Good Stock To Buy Now?
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.
Hedge Funds Are Selling Rhythm Pharmaceuticals, Inc. (RYTM)
In this article you are going to find out whether hedge funds think Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) is a good investment right now.
Hedge Funds Are Dumping Rhythm Pharmaceuticals, Inc. (RYTM)
At Insider Monkey, we pore over the filings of nearly 750 top investment firms every quarter, a process we have now completed for the latest reporting period.
Here's What Hedge Funds Think About Rhythm Pharmaceuticals, Inc. (RYTM)
Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts, usually don't make them change their opinion towards ...
Here's What Hedge Funds Think About Rhythm Pharmaceuticals, Inc. (RYTM)
Hedge funds are not perfect. They have their bad picks just like everyone else. Facebook, a stock hedge funds have loved, lost nearly 40% of its value at one point in 2018.
Billionaire Hedge Funds
